Alkeon Capital Management LLC Cerevel Therapeutics Holdings, Inc. Transaction History

Alkeon Capital Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$23.9 - $35.38 $880,141 - $1.3 Million	-36,826 Reduced 5.0%	699,695 $22.2 Million
Q1 2023 May 12, 2023	SELL	$22.82 - $35.32 $7.48 Million - $11.6 Million	-327,880 Reduced 30.8%	736,521 $18 Million
Q4 2022 Feb 13, 2023	SELL	$25.35 - $31.96 $2.64 Million - $3.33 Million	-104,195 Reduced 8.92%	1,064,401 $33.6 Million
Q3 2022 Nov 10, 2022	SELL	$25.5 - $41.42 $1.08 Million - $1.76 Million	-42,383 Reduced 3.5%	1,168,596 $33 Million
Q2 2022 Aug 15, 2022	SELL	$20.62 - $37.15 $10 Million - $18.1 Million	-486,397 Reduced 28.66%	1,210,979 $32 Million
Q1 2022 May 16, 2022	SELL	$23.5 - $35.38 $4.97 Million - $7.49 Million	-211,659 Reduced 11.09%	1,697,376 $59.4 Million
Q4 2021 Feb 14, 2022	SELL	$29.21 - $44.64 $35.6 Million - $54.3 Million	-1,217,400 Reduced 38.94%	1,909,035 $61.9 Million
Q3 2021 Nov 15, 2021	BUY	$21.26 - $38.85 $10.2 Million - $18.6 Million	480,000 Added 18.14%	3,126,435 $92.2 Million
Q2 2021 Aug 16, 2021	BUY	$12.56 - $29.69 $11.3 Million - $26.6 Million	896,435 Added 51.22%	2,646,435 $67.8 Million
Q4 2020 Feb 16, 2021	BUY	$9.82 - $18.27 $17.2 Million - $32 Million	1,750,000 New	1,750,000 $29 Million

242

154M

2.19M

3.87M

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Alkeon Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Alkeon Capital Management LLC with notifications on news.